Acumen Pharmaceuticals, Inc. (ABOS)
| Market Cap | 164.68M +156.1% |
| Revenue (ttm) | n/a |
| Net Income | -113.28M |
| EPS | -1.85 |
| Shares Out | 72.23M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 390,233 |
| Open | 2.350 |
| Previous Close | 2.390 |
| Day's Range | 2.260 - 2.400 |
| 52-Week Range | 0.971 - 3.600 |
| Beta | 0.32 |
| Analysts | Strong Buy |
| Price Target | 8.00 (+250.88%) |
| Earnings Date | May 12, 2026 |
About ABOS
Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops targeted therapies for the treatment of Alzheimer’s disease. It focuses on advancing a targeted immunotherapy drug candidate, sabirnetug (ACU193), which is in its Phase 2 ALTITUDE-AD clinical trial to target toxic soluble amyloid beta oligomers. Acumen Pharmaceuticals, Inc. has a collaboration and license agreement with Halozyme, Inc. for the development of a subcutaneous formulation of Sabirnetug, as well as with JCR Pharmaceuticals Co. Ltd for the development o... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 2 analysts, the average rating for ABOS stock is "Strong Buy." The 12-month stock price target is $8.0, which is an increase of 250.88% from the latest price.
News
Acumen Pharmaceuticals Transcript: Bank of America Global Healthcare Conference 2026
Sabirnetug, a monoclonal antibody targeting Aβ oligomers, is advancing through phase II trials with promising biomarker and safety data. Enhanced brain delivery programs and strategic partnerships aim to further improve efficacy, while the field anticipates combination therapies for Alzheimer's.
Acumen Pharmaceuticals Earnings Call Transcript: Q1 2026
Sabirnetug advanced in phase II with high trial retention and late 2026 data expected. Cash position is strong after a $35.75M raise, supporting operations into 2027. EBD program shows promising preclinical brain exposure and candidate selection is imminent.
Acumen Pharmaceuticals Reports First Quarter 2026 Financial Results and Business Highlights
NEWTON, Mass., May 12, 2026 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS) (“Acumen” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutics that t...
Acumen Pharmaceuticals to Participate in the Bank of America Securities 2026 Health Care Conference
NEWTON, Mass., May 07, 2026 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical company developing novel therapeutics that target toxic soluble amyloid ...
Acumen Pharmaceuticals to Report First Quarter Financial Results on May 12, 2026
NEWTON, Mass., May 05, 2026 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS) (“Acumen” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutics that t...
Acumen files to sell 10.83M shares of common stock for holders
16:31 EDT Acumen (ABOS) files to sell 10.83M shares of common stock for holders
Options Volatility and Implied Earnings Moves Today, March 26, 2026
Today, several major companies are expected to report earnings: Commercial Metals Company (CMC), Rockwell Med (RMTI), Blink Charging Co (BLNK), Veritone (VERI), The Lovesac Company (LOVE), Acumen Phar...
Acumen Pharmaceuticals Earnings Call Transcript: Q4 2025
Clinical and financial progress marked 2025, with ALTITUDE-AD phase II on track for late 2026 data and strong EBD preclinical results driving a $36M private placement. Cash reserves support operations into early 2027, and the pipeline is positioned for further growth.
Acumen Pharmaceuticals Reports Financial Results for the Year Ended December 31, 2025 and Business Highlights
NEWTON, Mass., March 26, 2026 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS) (“Acumen” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutics tha...
Acumen Pharmaceuticals to Report Fourth Quarter and Year-End 2025 Financial Results on March 26, 2026
NEWTON, Mass., March 19, 2026 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS) (“Acumen” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutics that...
Acumen Pharmaceuticals Transcript: Stifel 2026 Virtual CNS Forum
Sabirnetug, a selective antibody for toxic Abeta oligomers, is in phase II trials for Alzheimer's, with late 2026 data expected to validate its efficacy and safety. Enhanced brain delivery programs and a JCR partnership aim to further improve outcomes, with clinical entry targeted for 2027.
Acumen announces new research findings at Alzheimer’s and Parkinson’s conference
Acumen (ABOS) announced new research findings at the International Conference on Alzheimer’s and Parkinson’s Diseases and Related Neurological Disorders – AD/PD -, in Copenhagen. The data showcase eff...
Acumen price target raised to $8 from $7 at BTIG
BTIG raised the firm’s price target on Acumen (ABOS) to $8 from $7 and keeps a Buy rating on the shares. Recent updates suggest multiple TfR-binding scaffolds may meaningfully enhance…
Acumen announces $35.75M private placement
Acumen (ABOS) Pharmaceuticals has entered into a securities purchase agreement with certain institutional and accredited investors for a private placement of approximately $35.75 million of shares of ...
Acumen Pharmaceuticals Announces $35.75 Million Private Placement to Advance Potential Best-in-Class Molecules from Amyloid Beta Oligomer-Selective Enhanced Brain Delivery Portfolio
NEWTON, Mass., March 16, 2026 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS) (“Acumen” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutics tha...
Acumen Pharmaceuticals to Participate in the Stifel 2026 Virtual CNS Forum
NEWTON, Mass., March 10, 2026 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical company developing novel therapeutics that target toxic soluble amyloi...
Acumen price target raised to $7 from $4 at BTIG
BTIG raised the firm’s price target on Acumen (ABOS) to $7 from $4 and keeps a Buy rating on the shares. The rollout of Biogen’s (BIIB) two commercial drugs LEQEMBI…
Acumen initiated with a Buy at Lucid Capital
Lucid Capital initiated coverage of Acumen (ABOS) with a Buy rating and $6 price target The firm says Acumen is developing sabirnetug, an anti-amyloid beta oligomer monoclonal antibody that targets…
Acumen announces new research at CTAD on ACU193
Acumen (ABOS) Pharmaceuticals announced new research at the 18th Annual Clinical Trials on Alzheimer’s Disease, CTAD, conference, taking place December 1-4, 2025, in San Diego and online. Results from...
Acumen price target lowered to $8 from $9 at BofA
BofA lowered the firm’s price target on Acumen (ABOS) to $8 from $9 and keeps a Buy rating on the shares, citing an updated cash position following the company’s Q3…
Acumen first participant dosed in OLE portion of Phase 2 ALTITUDE-AD trial
Acumen (ABOS) Pharmaceuticals announced that the first participant has been dosed in the open-label extension, OLE, portion of its Phase 2 ALTITUDE-AD clinical trial evaluating sabirnetug in people wi...
Acumen Pharmaceuticals Earnings Call Transcript: Q3 2025
Phase II ALTITUDE-AD trial for sabirnetug is progressing, with open-label extension underway and top-line results expected in late 2026. Cash reserves of $136.1 million support operations into early 2027, while the EBD program advances through a strategic partnership with JCR Pharmaceuticals.
Acumen Pharmaceuticals Transcript: Stifel 2025 Healthcare Conference
Sabirnetug, a selective anti-oligomer antibody, is advancing in phase II for Alzheimer's, with promising biomarker and safety data from phase I. Strategic collaborations and innovative delivery approaches position the program for future growth, with key data expected next year.
Acumen appoints George Golumbeski as chairman of the board
Acumen (ABOS) Pharmaceuticals announced George Golumbeski, Ph.D., has joined its Board of Directors as Chairman. Dr. Golumbeski brings more than 30 years of experience in the biopharmaceuticals indust...
Acumen price target lowered to $4 from $11 at BTIG
BTIG analyst Thomas Shrader lowered the firm’s price target on Acumen (ABOS) to $4 from $11 and keeps a Buy rating on the shares. In a broader research note previewing…